

# Emerald Health Therapeutics Announces Chief Financial Officer Transition

Vancouver, British Columbia--(Newsfile Corp. - September 10, 2021) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQX: EMHTF) ("Emerald") announced today that its Chief Financial Officer, Jenn Hepburn, will be stepping down from her position at Emerald, effective October 15, 2021, to pursue other interests. She will continue in her role until that time to help with transition-related activities.

"Jenn's effort has been pivotal in the implementation of strong financial systems and controls, and in helping Emerald position itself for growth via its major restructuring and strategic shift over the last two years. We wish her much success in her future endeavors," said Riaz Bandali, President & CEO of Emerald. "We have engaged a well-known executive search firm that is experienced in the health, wellness and cannabis sectors to identify a new CFO who will complement our strong leadership team and help advance our go-forward strategy."

## About Emerald Health Therapeutics, Inc.

Emerald is committed to creating new consumer experiences with distinct recreational, medical and wellness-oriented cannabis products, with an emphasis on science-based innovation and product excellence.

Please visit [www.emeraldhealth.ca](http://www.emeraldhealth.ca) for more information or contact:

Jenn Hepburn, Chief Financial Officer  
1(800) 757 3536 Ext. #5  
Emerald Investor Relations  
(800) 757 3536 Ext. #5  
[invest@emeraldhealth.ca](mailto:invest@emeraldhealth.ca)

*Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*Cautionary Note Regarding Forward-Looking Statements: Certain statements made in this press release that are not historical facts are forward-looking statements and are subject to important risks, uncertainties and assumptions, both general and specific, which give rise to the possibility that actual results or events could differ materially from our expectations expressed in or implied by such forward-looking statements.*

*We cannot guarantee that any forward-looking statement will materialize, and readers are cautioned not to place undue reliance on these forward-looking statements. Such statements include uncertainty as a result of COVID-19 including any continued impact on production or operations; changes of law and regulations; changes of government; failure to obtain regulatory approvals; regulatory changes; receipt of amounts owing to Emerald; strategic development of Emerald; production and processing capacity of various facilities; expansion of facilities; failure to obtain necessary financing; results of scientific research; expectations around market and consumer demand and other patterns related to existing, new and planned product forms; timing for launch and shipment of new and existing product forms; ability of new product forms to capture sales and market share; results of production and sale activities; sales volumes; estimates around incremental sales and more generally estimates or predictions of actions of customers, suppliers, partners, distributors, competitors or regulatory authorities; changes in prices and costs of inputs; demand for labour; demand for products; failure of counter-parties to perform contractual obligations; statements regarding the future market of the*

*Canadian cannabis market; statements regarding Emerald's future economic performance; as well as the risk factors described in Emerald's annual information form and other regulatory filings. These statements are not historical facts but instead represent management beliefs regarding future events, many of which, by their nature are inherently uncertain and beyond management control.*

*The forward-looking statements contained in this press release represent our expectations as of the date hereof. Forward-looking statements are presented for the purpose of providing information about management's current expectations and plans and allowing investors and others to obtain a better understanding of our anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Emerald undertakes no obligations to update or revise such statements to reflect new circumstances or unanticipated events as they occur, unless required by applicable law.*



**emerald**  
HEALTH THERAPEUTICS

To view the source version of this press release, please visit  
<https://www.newsfilecorp.com/release/96163>